The Farnesoid X Receptor: Good for BAD

Diarrhea is a feature of several chronic intestinal disorders that are associated with increased delivery of bile acids into the colon. Although the prevalence of bile acid diarrhea is high, affecting approximately 1% of the adult population, current therapies often are unsatisfactory. By virtue of...

Full description

Saved in:
Bibliographic Details
Published in:Cellular and molecular gastroenterology and hepatology 2016-11, Vol.2 (6), p.725-732
Main Authors: Keely, Stephen J, Walters, Julian R.F
Format: Article
Language:English
Subjects:
Bile Acid Diarrhea
Chloride Secretion
Enterohepatic Circulation
Epithelium
FGF-19
Gastroenterology and Hepatology
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diarrhea is a feature of several chronic intestinal disorders that are associated with increased delivery of bile acids into the colon. Although the prevalence of bile acid diarrhea is high, affecting approximately 1% of the adult population, current therapies often are unsatisfactory. By virtue of its capacity to inhibit colonic epithelial fluid secretion and to down-regulate hepatic bile acid synthesis through induction of the ileal fibroblast growth factor 19 release, the nuclear bile acid receptor, farnesoid X receptor, represents a promising target for the development of new therapeutic approaches. Here, we review our current understanding of the pathophysiology of bile acid diarrhea and the current evidence supporting a role for farnesoid X receptor agonists in treatment of the disease.
ISSN:2352-345X
2352-345X
DOI:10.1016/j.jcmgh.2016.08.004